Skip to content
Compare prices
Prices checked against public provider pages Current, monitored and future routes kept separate Prescription medicines require clinical assessment

Updated 11 August 2026

Orforglipron vs semaglutide tablets UK: what is the difference?

This comparison is really about timing as much as medicine. Oral semaglutide now has a live UK weight-management route through the Wegovy pill. Orforglipron, branded as Foundayo in the United States, is still a future UK story rather than a current route you can buy here.

Available now

Wegovy pill

Oral semaglutide approved in the UK on 11 June 2026 and now on sale through private providers.

Different product

Rybelsus

Also oral semaglutide, but licensed for type 2 diabetes rather than weight loss.

Newly authorised

Orforglipron

Authorised by the MHRA on 10 August 2026. Watch for the first UK provider to dispense.

What orforglipron is

Orforglipron is an oral non-peptide GLP-1 medicine from Eli Lilly. In the United States it is branded as Foundayo and was approved there on 1 April 2026. That has made it a major search topic, but US approval does not create UK access on its own.

As of mid-2026 it does not have a UK licence, so it should still be treated as a tracked future medicine rather than a live option on a UK comparison page.

What semaglutide tablets mean in the UK now

Semaglutide tablets now sit in two distinct UK categories:

  • Wegovy pill: the oral semaglutide weight-management route, approved by the MHRA on 11 June 2026.
  • Rybelsus: oral semaglutide for type 2 diabetes, not a weight-loss tablet route.

That means oral semaglutide is no longer just a future concept in the UK. It already has a live route, which is why comparisons with orforglipron now need to start with “available now versus coming later”.

Dose ladders are different

Orforglipron and the Wegovy pill also differ in their published dose ladders.

  • Orforglipron / Foundayo: 0.8mg, 2.5mg, 5.5mg, 9mg, 14.5mg, 17.2mg
  • Wegovy pill: 1.5mg, 4mg, 9mg, 25mg

Those ladders should not be compared as if one is simply a stronger or weaker version of the other. They are different products on different regulatory timelines.

UK access and price difference

This is where the comparison becomes simplest:

  • Wegovy pill: available now in the UK with live public provider prices.
  • Orforglipron: no live UK route, no legitimate current UK standard price.

If your question is what you can access today, semaglutide wins by default because it is the only route with a real UK market. If your question is what may matter later, orforglipron stays on the watchlist for 2027 and beyond.

What not to claim yet

A careful UK comparison should not say that orforglipron has already been submitted to the MHRA or that a UK launch date is confirmed. It should also avoid pretending there is already a buyable UK Foundayo price.

The honest current framing is straightforward: the semaglutide tablet route is live now, while orforglipron is still a future UK medicine.

Common questions

Orforglipron vs semaglutide tablets FAQ

Can you get orforglipron in the UK now?

Not yet. Orforglipron was authorised by the MHRA on 10 August 2026, but no UK provider was dispensing it when we checked on 11 August 2026.

Which oral GLP-1 tablet is available in the UK now?

The live weight-management route is the Wegovy pill. Rybelsus is available too, but in type 2 diabetes context.

Does Foundayo have a UK price?

No. Without a UK licence and a real public provider route, there is no legitimate current UK standard price to compare.